Search research articles
Contact Us
Filters
Showing results (171-180 of 233) with videos related to
Page
of 24
Sort By:
JCI Insight
|
June 6, 2020
Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease
Yan Zhao, Ling Qin, Ping Zhang, et al.
Kidney International Reports
|
June 15, 2026
Randomized Controlled Study of Sirolimus-Coated Balloons for Dysfunctional Hemodialysis Fistulas
Chieh Suai Tan, Ru Yu Tan, Pei Ho, et al.
Frontiers in Immunology
|
March 22, 2021
Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune Phenotype
Emily Fraser, Laura Denney, Agne Antanaviciute, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy
|
March 20, 2026
Consortium-Based Patient and Public Involvement and Engagement for Long COVID Research: A Pirit-Focused Impact Evaluation of the PHOSP-COVID Study
Linzy Houchen-Wolloff, Joanna Bell, Rebecca Pritchard, et al.
Science Signaling
|
June 28, 2018
Thyroid hormone receptor and ERRα coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function
Brijesh K Singh, Rohit A Sinha, Madhulika Tripathi, et al.
JCI Insight
|
April 14, 2017
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza
Suzanne L Cole, Jake Dunning, Wai Ling Kok, et al.
Trials
|
August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial
Tom Wilkinson, Rupert Dixon, Clive Page, et al.
The Lancet. Respiratory Medicine
|
December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Benjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
Nature Biotechnology
|
August 28, 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens
Frank Wegmann, Kate H Gartlan, Ali M Harandi, et al.
ERJ Open Research
|
October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
Page
of 24
Search research articles
Search
Showing results (171-180 of 233) with videos related to
Sort By:
Page
of 24
JCI Insight
|
June 6, 2020
Longitudinal COVID-19 profiling associates IL-1RA and IL-10 with disease severity and RANTES with mild disease
Yan Zhao, Ling Qin, Ping Zhang, et al.
Kidney International Reports
|
June 15, 2026
Randomized Controlled Study of Sirolimus-Coated Balloons for Dysfunctional Hemodialysis Fistulas
Chieh Suai Tan, Ru Yu Tan, Pei Ho, et al.
Frontiers in Immunology
|
March 22, 2021
Multi-Modal Characterization of Monocytes in Idiopathic Pulmonary Fibrosis Reveals a Primed Type I Interferon Immune Phenotype
Emily Fraser, Laura Denney, Agne Antanaviciute, et al.
Health Expectations : an International Journal of Public Participation in Health Care and Health Policy
|
March 20, 2026
Consortium-Based Patient and Public Involvement and Engagement for Long COVID Research: A Pirit-Focused Impact Evaluation of the PHOSP-COVID Study
Linzy Houchen-Wolloff, Joanna Bell, Rebecca Pritchard, et al.
Science Signaling
|
June 28, 2018
Thyroid hormone receptor and ERRα coordinately regulate mitochondrial fission, mitophagy, biogenesis, and function
Brijesh K Singh, Rohit A Sinha, Madhulika Tripathi, et al.
JCI Insight
|
April 14, 2017
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza
Suzanne L Cole, Jake Dunning, Wai Ling Kok, et al.
Trials
|
August 2, 2020
ACCORD: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalised Patients: A structured summary of a study protocol for a randomised controlled trial
Tom Wilkinson, Rupert Dixon, Clive Page, et al.
The Lancet. Respiratory Medicine
|
December 19, 2021
Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial
Benjamin A Fisher, Tonny Veenith, Daniel Slade, et al.
Nature Biotechnology
|
August 28, 2012
Polyethyleneimine is a potent mucosal adjuvant for viral glycoprotein antigens
Frank Wegmann, Kate H Gartlan, Ali M Harandi, et al.
ERJ Open Research
|
October 23, 2023
A randomised phase 2a study to investigate the effects of blocking interleukin-33 with tozorakimab in patients hospitalised with COVID-19: ACCORD-2
Tom Wilkinson, Anthony De Soyza, Miles Carroll, et al.
Page
of 24